Brief: Durect Corporation Qtrly Net Loss Per Common Share, Basic And Diluted $0.03

DURECT

07/03/2022 21:14

March 7 (Reuters) - DURECT Corp  DRRX.O :
    * DURECT CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS AND UPDATE OF PROGRAMS
    * DURECT CORP - SIGNED A LICENSING AGREEMENT FOR POSIMIR®
FOR UP
TO $136M
    * DURECT CORP - QTRLY TOTAL REVENUES WERE $7.3 MILLION
    * DURECT CORP - QTRLY TOTAL REVENUES WERE $7.3 MILLION
    * DURECT CORP - COMMERCIAL LAUNCH OF POSIMIR BY OUR
LICENSEE,
INNOCOLL PHARMACEUTICALS; EXPECTED IN Q2 2022
    * DURECT CORP - QTRLY NET LOSS PER COMMON SHARE, BASIC AND
DILUTED
$0.03

Source text for Eikon:  ID:nPn1RLypGa 
Further company coverage:  DRRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))